Trexquant Investment LP purchased a new position in Illumina (NASDAQ:ILMN) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 8,498 shares of the life sciences company’s stock, valued at approximately $2,009,000.
Other institutional investors have also recently modified their holdings of the company. Financial Gravity Companies Inc. purchased a new position in Illumina in the fourth quarter worth approximately $106,000. SeaCrest Wealth Management LLC purchased a new position in Illumina in the fourth quarter worth approximately $154,000. Captrust Financial Advisors purchased a new position in Illumina in the fourth quarter worth approximately $165,000. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its stake in Illumina by 113.9% in the fourth quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 770 shares of the life sciences company’s stock worth $168,000 after acquiring an additional 410 shares during the last quarter. Finally, Riverbridge Partners LLC purchased a new position in Illumina in the fourth quarter worth approximately $202,000. Institutional investors own 91.59% of the company’s stock.
ILMN stock traded up $1.75 on Friday, hitting $270.20. The company’s stock had a trading volume of 7,934 shares, compared to its average volume of 891,707. Illumina has a 1 year low of $264.12 and a 1 year high of $267.94. The company has a market cap of $39.52 billion, a price-to-earnings ratio of 67.76, a price-to-earnings-growth ratio of 2.76 and a beta of 0.86. The company has a debt-to-equity ratio of 0.23, a current ratio of 2.71 and a quick ratio of 2.41.
A number of research analysts recently issued reports on ILMN shares. BidaskClub upgraded shares of Illumina from a “hold” rating to a “buy” rating in a research note on Saturday, March 10th. Morgan Stanley boosted their price objective on shares of Illumina from $170.00 to $180.00 and gave the stock an “underweight” rating in a research report on Wednesday, April 25th. Zacks Investment Research upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $270.00 price objective for the company in a research report on Monday, April 16th. Citigroup upgraded shares of Illumina from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $260.00 to $275.00 in a research report on Monday, February 5th. Finally, Barclays boosted their price objective on shares of Illumina from $215.00 to $235.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 25th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $251.14.
In other Illumina news, EVP Omead Ostadan sold 1,329 shares of the business’s stock in a transaction on Friday, March 2nd. The shares were sold at an average price of $222.66, for a total value of $295,915.14. Following the transaction, the executive vice president now directly owns 29,392 shares of the company’s stock, valued at approximately $6,544,422.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Robert S. Epstein sold 250 shares of the business’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $231.25, for a total transaction of $57,812.50. Following the completion of the transaction, the director now directly owns 7,088 shares in the company, valued at $1,639,100. The disclosure for this sale can be found here. In the last quarter, insiders sold 16,614 shares of company stock valued at $4,018,424. 0.54% of the stock is owned by insiders.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.